Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Kaplan-Meier Approach

Kaplan-Meier Approach

The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...

Comparing the Survival Analysis of Two or More Groups

Comparing the Survival Analysis of Two or More Groups

Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and Cox...

Detection of Gross Error: The Q Test

Detection of Gross Error: The Q Test

When one or more data points appear far from the rest of the data, there is a need to determine whether they are outliers and whether they should be eliminated from the data set to ensure an accurate representation of the measured value. In many cases, outliers arise from gross errors (or human errors) and do not accurately reflect the underlying phenomenon. In some cases, however, these apparent outliers reflect true phenomenological differences. In these cases, we can use statistical methods...

Quantifying and Rejecting Outliers: The Grubbs Test

Quantifying and Rejecting Outliers: The Grubbs Test

Sometimes, a data set can have a recorded numerical observation that greatly deviates from the rest of the data. Assuming that the data is normally distributed, a statistical method called the Grubbs test can be used to determine whether the observation is truly an outlier. To perform a two-tailed Grubbs test, first, calculate the absolute difference between the outlier and the mean. Then, calculate the ratio between this difference and the standard deviation of the sample. This number is...

Censoring Survival Data

Censoring Survival Data

Survival analysis is a statistical method used to analyze time-to-event data, often employed in fields such as medicine, engineering, and social sciences. One of the key challenges in survival analysis is dealing with incomplete data, a phenomenon known as "censoring." Censoring occurs when the event of interest (such as death, relapse, or system failure) has not occurred for some individuals by the end of the study period or is otherwise unobservable, and it might have many different reasons...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Individualised progesterone receptor modulator prevention strategies for triple-negative breast cancer in BRCA1 pathogenic variant carriers.

NPJ breast cancer·2026

Same author

Benefit-risk balance of S-1 versus UFT as adjuvant chemotherapy for stage II/III rectal cancer (JFMC35-C1: ACTS-RC).

The oncologist·2026

Same author

Immunohistochemical characterization of nerve fibers supplying canine elbow joint capsule.

BMC veterinary research·2026

Same author

Methods for Evaluation of Surrogate Endpoints for Health Technology Assessment Decision Making: A Good Practices Report of an ISPOR Task Force.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026

Same author

Enhancing Clinical Cancer Research Through Sharing of Data and Biospecimens.

JAMA oncology·2025

Same author

Regional variation in clinical-trial risks: a large-scale analysis of 585 clinical trials.

BMJ open·2025

Search research articles

Related Experiment Video

Updated: Jul 19, 2026

An R-Based Landscape Validation of a Competing Risk Model

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

Surrogate threshold effect: an alternative measure for meta-analytic surrogate endpoint validation.

Tomasz Burzykowski¹, Marc Buyse

¹Center for Statistics, Hasselt University, Agoralaan (bldg. D), B3590 Diepenbeek, Belgium. tomasz.burzykowski@uhasselt.be

Pharmaceutical Statistics

|November 4, 2006

Summary

This study introduces the surrogate threshold effect (STE) to better interpret surrogate endpoint validation in clinical trials. STE provides a clinically meaningful measure for predicting true endpoint treatment effects, improving trial efficiency.

Related Experiment Videos

Last Updated: Jul 19, 2026

An R-Based Landscape Validation of a Competing Risk Model

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

Area of Science:

Biostatistics
Clinical Trial Design
Pharmacometrics

Background:

Surrogate endpoints accelerate clinical trials but require rigorous validation.
Existing validation metrics like Rtrial² lack intuitive interpretation.
Accurate surrogate endpoint validation is crucial for drug development efficiency.

Purpose of the Study:

Introduce and define the surrogate threshold effect (STE) for improved surrogate endpoint interpretation.
Provide a clinically relevant metric for assessing surrogate endpoint validity.
Enhance the practical utility of surrogate endpoints in therapeutic areas.

Main Methods:

Proposed a novel metric, the surrogate threshold effect (STE).
Defined STE as the minimum surrogate treatment effect predicting a non-zero true endpoint effect.
Utilized a meta-analytic framework for validation.

Main Results:

The STE offers a natural clinical interpretation, unlike Rtrial².
STE quantifies the minimum surrogate effect needed to infer a true endpoint effect.
This new metric aids in practical decision-making for surrogate endpoint use.

Conclusions:

The surrogate threshold effect (STE) provides a valuable and interpretable measure for surrogate endpoint validation.
STE enhances the practical application of surrogate endpoints in clinical research.
This approach facilitates more efficient and reliable clinical trial design.